DIM Sartorius Stedim Biotech SA

Sartorius Stedim Biotech releases Universal Registration Document 2023

Sartorius Stedim Biotech SA / Key word(s): Annual Results
Sartorius Stedim Biotech releases Universal Registration Document 2023

16-Feb-2024 / 10:00 CET/CEST

Aubagne, February 16, 2024

Sartorius Stedim Biotech releases Universal Registration Document 2023

Sartorius Stedim Biotech, a leading partner of the biopharma industry, has released its Universal Registration Document 2023 including the Annual Financial Report today. The document is available under the following link: . 


Financial calendar 
March 26, 2024     Annual General Meeting 
April 18, 2024        Publication of the quarterly figures January to March 2024 
July 19, 2024         Publication of the half-year figures January to June 2024 
October 17, 2024   Publication of the nine-month figures January to September 2024


A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and economically. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2023, the company generated sales revenue of around 2.8 billion euros. Currently, more than 10,600 employees are working for customers around the globe.


Contact
Timo Lindemann
External Communications 
+49 (0)551.308.4724
 


Follow Sartorius on .
Attachment

File:

Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Language: English
Issuer: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone:
E-mail:
Internet: -stedim.com
ISIN: FR0013154002
EQS News ID: 1838423

 
End of Announcement - EQS News Service

1838423  16-Feb-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1838423&application_name=news&site_id=research_pool
EN
16/02/2024

Underlying

DIMSartorius Stedim Biotech SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sartorius Stedim Biotech SA

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan
EUR 4672.00
DIM Sartorius Stedi...

Sartorius Stedim - More Downside to Come (SELL, TP EUR150 [165], 9 pgs...

The capitulation may be upon us. The order book continues to show weakness & contrary to the befuddling Q423 sales strength, equipment sales look likely to stay weak as CDMO’s reduce CAPEX after 3yrs of turbo charged growth. We now question the trend growth rate as we believe that market share gains will be minimal, CDMO CAPEX will recover very slowly & M&A is unlikely to contribute as much as it did in the past. Moreover, we expect DIM to add significant capacity in the coming 24mths, which is ...

DIM SARTORIUS STEDIM BIOTECH SA
04/19/24 April 19, 2024 1 EN
Maissa Keskes ... (+2)
  • Maissa Keskes
  • Stephane Houri
FP TOTAL SE
EDEN EDENRED SA
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
BN DANONE SA
KPN ROYAL KPN NV
VOLV B VOLVO AB CLASS B
ABB ABB LTD.
SRT3 SARTORIUS AG PREF
NOKIA NOKIA OYJ
REE RED ELECTRICA CORP. SA
ENI ENI S.P.A.
SCHP SCHINDLER HOLDING AG PREF
CAP CAPGEMINI SE
EZJ EASYJET PLC
REP REPSOL SA
DIM SARTORIUS STEDIM BIOTECH SA
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
BC BRUNELLO CUCINELLI S.P.A.
HLAG HAPAG-LLOYD AG
BHP BHP GROUP LTD
ASML ASML HOLDING NV
BP. BP P.L.C.
FDJ LA FRANCAISE DES JEUX SA
SHEL SHELL PLC
SGSN SGS SA
04/18/24 April 18, 2024 1 EN
Maissa Keskes ... (+2)
  • Maissa Keskes
  • Stephane Houri
FP TOTAL SE
EDEN EDENRED SA
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
BN DANONE SA
KPN ROYAL KPN NV
VOLV B VOLVO AB CLASS B
ABB ABB LTD.
SRT3 SARTORIUS AG PREF
NOKIA NOKIA OYJ
REE RED ELECTRICA CORP. SA
ENI ENI S.P.A.
SCHP SCHINDLER HOLDING AG PREF
CAP CAPGEMINI SE
EZJ EASYJET PLC
REP REPSOL SA
DIM SARTORIUS STEDIM BIOTECH SA
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
BC BRUNELLO CUCINELLI S.P.A.
HLAG HAPAG-LLOYD AG
BHP BHP GROUP LTD
ASML ASML HOLDING NV
BP. BP P.L.C.
FDJ LA FRANCAISE DES JEUX SA
SHEL SHELL PLC
SGSN SGS SA
04/18/24 April 18, 2024 1 FR
Oliver Metzger
  • Oliver Metzger
DIM Sartorius Stedi...

Sartorius Stedim Biotech : Q1 review -Some stabilisation, but sales an...

>Q1 with some stabilisation – sales and order intake weaker than expected - Q1 2024 revenues of € 667m (-8.1% y-o-y,-2%/-4% vs ODDO BHF/consensus) were impacted by an organic decline of 9.4%. The decline in constant currencies was at -6.7%. Sartorius Stedim Biotech was impacted by mixed dynamics across its portfolio and regions. Demand continued to normalise the consumables business with positive order momentum, which indicates further progress in destocking. Simultan...

DIM SARTORIUS STEDIM BIOTECH SA
04/18/24 April 18, 2024 1 EN
 PRESS RELEASE
Free
DIM Sartorius Stedi...

Sartorius Stedim Biotech publishes unaudited first quarter results for...

Sartorius Stedim Biotech SA / Key word(s): Quarter Results Sartorius Stedim Biotech publishes unaudited first quarter results for 2024 18-Apr-2024 / 07:02 CET/CEST   Aubagne, France | April 18, 2024 Sartorius Stedim Biotech publishes unaudited first quarter results for 2024   Sales revenue of 667 million euros, in constant currencies1 - 9.4 percent organically1and - 6.7 percent including acquisitions2(reported: - 8.2 percent) Order intake up 13.9 percent to 676 million euros (reported: 12.5 percent) with significant growth in recurring business, while demand from China remains we...

April 18, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch